Tvardi Therapeutics (TVRD) Stock Analysis: AI Score & Alternative Data
Demand signals are heating up for Tvardi Therapeutics
Is Tvardi Therapeutics a buy right now? The alternative data says hold. This TVRD stock analysis is built on the 25+ alternative data signals AltIndex tracks on Tvardi Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 55/100: a Hold. The stock trades at $3.61 with a $29M market cap.
The data leans positive over the past 90 days — web traffic up 14.5% to 2K monthly visits — but the move hasn’t been broad enough to lift TVRD into buy territory yet.
TVRD’s broader alt-data profile also covers headcount (20 employees, according to LinkedIn), X followers (129), Reddit mentions (1 a day), and sentiment (77/100). Every signal links to its own page with full history, the TVRD technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on TVRD is just below.
Tvardi Therapeutics AI Stock Analysis
Tvardi Therapeutics is a biotechnology company focused on the development of small-molecule inhibitors that target STAT3, a protein implicated in multiple types of cancer and fibrotic diseases. The company's pipeline includes promising candidates that are undergoing various stages of clinical trials.
Analysis generated July 2, 2026.
Recent Tvardi Therapeutics Stock Alerts
|
Tvardi Therapeutics | July 10 Price is down by -12.6% in the last 24h. |
|
Tvardi Therapeutics | July 9 Price is down by -11.9% in the last 24h. |
|
Tvardi Therapeutics | July 8 Price is up by 9.4% in the last 24h. |
|
Tvardi Therapeutics | July 7 Price is up by 53.7% in the last 24h. |
Tvardi Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 2K | 14.5% | |
| LinkedIn Employees | 20 | N/A | |
| Sentiment | 77 | N/A | |
| Reddit Mentions | 1 | N/A | |
| X Mentions | 12 | N/A | |
| Stocktwits Mentions | 689 | N/A | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 493 | N/A | |
| X Followers | 129 | N/A |
About Tvardi Therapeutics (TVRD)
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering innovative therapies for oncology and other critical medical challenges. Utilizing its proprietary drug discovery platform, Tvardi focuses on the development of small molecule therapies that target protein degradation pathways to offer therapeutic advantages in cancer treatment. Its lead candidate, TVB-2640, is designed to undermine cancer cell survival mechanisms, showcasing the company's dedication to advancing treatment options for patients facing malignancies. With a strong pipeline and a commitment to scientific excellence, Tvardi is well-positioned to transform the cancer therapeutics arena and improve patient outcomes.
| Price | $3.61 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $29M |
| Year Range | $2 – $43 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Tvardi Therapeutics News
View more →| No recent news for TVRD. |
Tvardi Therapeutics Earnings & Financial Performance
View all earnings →Tvardi Therapeutics Insider Trading Activity
View all →| No recent insider transactions on file. |
Tvardi Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Tvardi Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Actinium PharmaceuticalsATNM |
$0.97 0.0% | $30M | 44 |
 |
Dare BioscienceDARE |
$2.07 2.0% | $31M | 52 |
 |
China Pharma HoldingCPHI |
$0.57 11.0% | $26M | 51 |
 |
BioXcel TherapeuticsBTAI |
$0.82 2.7% | $26M | 38 |
 |
Senti BiosciencesSNTI |
$0.99 0.8% | $32M | 52 |
Explore Tvardi Therapeutics Data
Frequently Asked Questions: Tvardi Therapeutics (TVRD)
Tvardi Therapeutics has an AltIndex AI Score of 55/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
55/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Tvardi Therapeutics (TVRD) stock is $3.61 with a market cap of $29M.
As of today, Tvardi Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest Tvardi Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Tvardi Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The TVRD stock price chart above shows Tvardi Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Tvardi Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Tvardi Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
